Unknown PHASE1 INTERVENTIONAL 1-arm NCT06144385

A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma

Sponsor: Shanghai Ming Ju Biotechnology Co., Ltd.

Conditions Hepatic Cell Carcinoma Liver Carcinoma

Updated 5 times since 2023 Last updated: Dec 27, 2023 Started: Mar 24, 2022 Primary completion: Mar 31, 2024 Completion: Dec 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Hepatic Cell Carcinoma and Liver Carcinoma, this trial is ongoing. The trial is conducted by Shanghai Ming Ju Biotechnology Co., Ltd. and has accumulated 5 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Jan 2026 — Present [monthly]

Unknown PHASE1

Status: Recruiting → Unknown
Sep 2024 — Jan 2026 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Feb 2024 — Jul 2024 [monthly]

Recruiting PHASE1
Dec 2023 — Feb 2024 [monthly]

Recruiting PHASE1

First recorded

Mar 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Ming Ju Biotechnology Co., Ltd.

Data source: Shanghai Ming Ju Biotechnology Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Wuhan, China